Mirvetuximab soravtansine is a Monoclonal Antibody Conjugated owned by ImmunoGen, and is involved in 15 clinical trials, of which 4 were completed, and 11 are ongoing.
Mirvetuximab Soravtansine selectively targets and kills cancer cells expressing folate receptor 1 (FOLR1). Folate receptor alpha (FRalpha) is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies. Folate enhances the differential specificity of conjugated anti-cancer drugs by targeting folate receptor (FR)-positive cancer cells. Folate receptor, a tumor associated glycosylphosphatidylinositol anchored protein, can actively internalize bound folates and folate conjugated compounds via receptor-mediated endocytosis. IMGN853 also serves to target the TAP compound specifically to cancer cells, and the cell-killing agent serves to destroy these cells.
The revenue for Mirvetuximab soravtansine is expected to reach a total of $13.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mirvetuximab soravtansine NPV Report.
Mirvetuximab soravtansine is originated and owned by ImmunoGen.
Mirvetuximab soravtansine Overview
Mirvetuximab Soravtansine (Elahere, Mirvetuximab Soravtansine-GYNX) is an immunoconjugate consisting of the humanized monoclonal antibody. It is formulated as a solution for the intravenous route of administration, Elahere is indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Mirvetuximab soravtansine (IMGN-853) is under development for the treatment of FR alpha positive solid tumors such as metastatic triple negative breast cancer, platinum-resistant, advanced high-grade epithelial ovarian cancer, advanced-stage ovarian cancer (first line), primary peritoneal cancer and fallopian tube cancer. The drug candidate is administered through intravenous route. It is an antibody-drug conjugate consisting of cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, which selectively binds to folate receptor 1 (FOLR1). The drug candidate is based on targeted antibody payload (TAP) technology. It was also under development for the treatment of renal cell adenocarcinoma, endometrial cancer and non-small cell lung adenocarcinoma,
ImmunoGen is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGenorporates its proprietary product development ADC technology to enhance the anticancer activity of monoclonal antibodies. The company has direct operations in the US, Ireland, and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.
The company reported revenues of (US Dollars) US$69.9 million for the fiscal year ended December 2021 (FY2021), a decrease of 47.2% over FY2020. The operating loss of the company was US$125.1 million in FY2021, compared to an operating loss of US$22.4 million in FY2020. The net loss of the company was US$139.3 million in FY2021, compared to a net loss of US$44.4 million in FY2020. The company reported revenues of US$15.4 million for the third quarter ended September 2022, an increase of 8.6% over the previous quarter.
Quick View – Mirvetuximab soravtansine
|Highest Development Stage|